Skip Nav Destination
            
    
            
 
    
    
        
            
                
                    
                        
                        
                            
                        
                    
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                     
    
                    
                    
        
        International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
        
     
    
                    
        
                    
        
        Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
                    
                
            
    
    
    
        
        
        
     
    
                    
        
                    
        
        Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                    
        
                    
                 
    
                    
        
        
     
    
                     
    
                     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
        
    
    
    
            
        
 
    
    
 
    
    
         
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
Table of Contents
BLOOD COMMENTARIES
SPECIAL REPORT
        
        International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Frits van Rhee,Peter Voorhees,Angela Dispenzieri,Alexander Fosså,Gordan Srkalovic,Makoto Ide,Nikhil Munshi,Stephen Schey,Matthew Streetly,Sheila K. Pierson,Helen L. Partridge,Sudipto Mukherjee,Dustin Shilling,Katie Stone,Amy Greenway,Jason Ruth,Mary Jo Lechowicz,Shanmuganathan Chandrakasan,Raj Jayanthan,Elaine S. Jaffe,Heather Leitch,Naveen Pemmaraju,Amy Chadburn,Megan S. Lim,Kojo S. Elenitoba-Johnson,Vera Krymskaya,Aaron Goodman,Christian Hoffmann,Pier Luigi Zinzani,Simone Ferrero,Louis Terriou,Yasuharu Sato,David Simpson,Raymond Wong,Jean-Francois Rossi,Sunita Nasta,Kazuyuki Yoshizaki,Razelle Kurzrock,Thomas S. Uldrick,Corey Casper,Eric Oksenhendler,David C. Fajgenbaum
            
        
    
            REVIEW ARTICLES
CLINICAL TRIALS AND OBSERVATIONS
        
        Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
        
        
            
        
                    
                        CME
                    
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Matthieu Jestin,on behalf of the French Thrombotic Microangiopathies Reference Center,Ygal Benhamou,on behalf of the French Thrombotic Microangiopathies Reference Center,An-Sofie Schelpe,on behalf of the French Thrombotic Microangiopathies Reference Center,Elien Roose,on behalf of the French Thrombotic Microangiopathies Reference Center,François Provôt,on behalf of the French Thrombotic Microangiopathies Reference Center,Lionel Galicier,on behalf of the French Thrombotic Microangiopathies Reference Center,Miguel Hié,on behalf of the French Thrombotic Microangiopathies Reference Center,Claire Presne,on behalf of the French Thrombotic Microangiopathies Reference Center,Pascale Poullin,on behalf of the French Thrombotic Microangiopathies Reference Center,Alain Wynckel,on behalf of the French Thrombotic Microangiopathies Reference Center,Samir Saheb,on behalf of the French Thrombotic Microangiopathies Reference Center,Christophe Deligny,on behalf of the French Thrombotic Microangiopathies Reference Center,Aude Servais,on behalf of the French Thrombotic Microangiopathies Reference Center,Stéphane Girault,on behalf of the French Thrombotic Microangiopathies Reference Center,Yahsou Delmas,on behalf of the French Thrombotic Microangiopathies Reference Center,Tarik Kanouni,on behalf of the French Thrombotic Microangiopathies Reference Center,Alexandre Lautrette,on behalf of the French Thrombotic Microangiopathies Reference Center,Dominique Chauveau,on behalf of the French Thrombotic Microangiopathies Reference Center,Christiane Mousson,on behalf of the French Thrombotic Microangiopathies Reference Center,Pierre Perez,on behalf of the French Thrombotic Microangiopathies Reference Center,Jean-Michel Halimi,on behalf of the French Thrombotic Microangiopathies Reference Center,Anne Charvet-Rumpler,on behalf of the French Thrombotic Microangiopathies Reference Center,Mohamed Hamidou,on behalf of the French Thrombotic Microangiopathies Reference Center,Pascal Cathébras,on behalf of the French Thrombotic Microangiopathies Reference Center,Karen Vanhoorelbeke,on behalf of the French Thrombotic Microangiopathies Reference Center,Agnès Veyradier,on behalf of the French Thrombotic Microangiopathies Reference Center,Paul Coppo,on behalf of the French Thrombotic Microangiopathies Reference Center
            
        
    
            LYMPHOID NEOPLASIA
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
            Michael A. Chapman,Jonathan Sive,John Ambrose,Claire Roddie,Nicholas Counsell,Anna Lach,Mahnaz Abbasian,Rakesh Popat,Jamie D. Cavenagh,Heather Oakervee,Matthew J. Streetly,Stephen Schey,Mickey Koh,Fenella Willis,Andres E. Virchis,Josephine Crowe,Michael F. Quinn,Gordon Cook,Charles R. Crawley,Guy Pratt,Mark Cook,Nivette Braganza,Toyin Adedayo,Paul Smith,Laura Clifton-Hadley,Roger G. Owen,Pieter Sonneveld,Jonathan J. Keats,Javier Herrero,Kwee Yong
            
        
    
            PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
        
        Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death
        
        
            
        
                    
                        Clinical Trials & Observations
                    
                    
                        Brief Report
                    
        
            
    
        
            Shigeharu Ueki,Takahiro Tokunaga,Rossana C. N. Melo,Hidekazu Saito,Kohei Honda,Mineyo Fukuchi,Yasunori Konno,Masahide Takeda,Yohei Yamamoto,Makoto Hirokawa,Shigeharu Fujieda,Lisa A. Spencer,Peter F. Weller
            
        
    
            TRANSPLANTATION
Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice
            Vedran Radojcic,Katelyn Paz,Jooho Chung,Jing Du,Eric T. Perkey,Ryan Flynn,Sanja Ivcevic,Michael Zaiken,Ann Friedman,Minhong Yan,Maria A. Pletneva,Stefanie Sarantopoulos,Christian W. Siebel,Bruce R. Blazar,Ivan Maillard
            
        
    
            There is a Blood Commentary on this article in this issue.
LETTERS TO BLOOD
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
- 
        
            Cover Image
        
        Cover Image![issue cover]()  Galectin-10 forms Charcot-Leyden crystals (green, slender, bipyramidal structures) in nasal polyp tissue from a patient with eosinophilic chronic rhinosinusitis. The image shows a confocal image of galectin-10 (green), major basic protein (red), and DNA (blue) staining. See the article by Ueki et al on page 2183. 
- PDF Icon Front MatterFront Matter
- PDF Icon Table of ContentsTable of Contents
- PDF Icon Back MatterBack Matter
- PDF Icon Editorial BoardEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
 
                    





